Xenon's Azetukalner Hits Primary Endpoint in Phase 3 Focal Seizure Trial
Event summary
- Xenon's Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS) met primary endpoint, with -53.2% median percent change in seizure frequency vs. -10.4% for placebo (p=0.000000000006).
- 25 mg dose outperformed Phase 2b study, showing -42.7% placebo-adjusted reduction in seizure frequency.
- Azetukalner was generally well-tolerated, with dizziness and headache as the most common adverse events.
- Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026.
The big picture
Xenon's positive Phase 3 results for azetukalner represent a significant milestone in the epilepsy treatment landscape, where up to 50% of patients still live with uncontrolled seizures. The study's high placebo-adjusted efficacy and favorable safety profile could position azetukalner as a preferred medication, addressing the critical need for new therapeutic approaches in focal onset seizures. The upcoming NDA submission and potential approval in 2026 will be key catalysts for Xenon's growth strategy.
What we're watching
- Regulatory Approval
- Whether the FDA will approve azetukalner based on the Phase 3 data and the planned Q3 2026 NDA submission.
- Market Differentiation
- How azetukalner's differentiated KV7 mechanism of action and ease-of-use attributes will position it against existing epilepsy treatments.
- Commercialization Strategy
- The pace at which Xenon can advance its commercial-readiness activities in anticipation of its first commercial launch.
Related topics